Hutchmed (China) Limited (Hutchmed) has announced that it has completed patient enrollment of FRESCO-2, a phase III registration study of fruquintinib, an investigational treatment for the treatment of patients with metastatic colorectal cancer (CRC) in the US, Europe, Japan and Australia. The enrollment goal was reached on December 2, 2021.
Recruitment of 687 patients globally completed in fifteen months, ahead of schedule. FRESCO-2 primary objective is to confirm overall clinical benefit seen in the China FRESCO pivotal study and to support global registrations.
FRESCO-2 is a randomized, double-blind, placebo-controlled, multicenter trial being conducted in patients with metastatic CRC. The primary endpoint of the study is overall survival (
